xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05969574</url>
    </required_header>
    <id_info>
      <org_study_id>2305-ABU-007-LM</org_study_id>
      <nct_id>NCT05969574</nct_id>
    </id_info>
    <brief_title>Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?</brief_title>
    <official_title>Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages? A Prospective Observational Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>ART Fertility Clinics LLC</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>ART Fertility Clinics LLC</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study aims to explore the potential correlation between decreased ovarian reserve and&#xD;
        previous history of early miscarriage.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        By investigating the prevalence of low ovarian reserve (LOR) in populations with specific&#xD;
        reproductive histories (such as recurrent pregnancy loss, G0, and ectopic pregnancy), as well&#xD;
        as the aneuploidy rates of embryos produced with Preimplantation Genetic Testing for&#xD;
        Aneuploidies (PGT-A), Investigators can better understand how LOR impacts fertility outcomes&#xD;
        in these populations. This information can be used to inform clinical decision-making, such&#xD;
        as whether participants with LOR should consider alternative or whether they would benefit&#xD;
        from additional interventions to improve ovarian function.&#xD;
  &#xD;
        Ultimately, by improving our understanding of how LOR impacts fertility outcomes in specific&#xD;
        populations, Investigators can help to improve the overall success rates of infertility&#xD;
        treatment, reduce anxiety, and distress, and help participants achieve goals of becoming&#xD;
        parents.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 15, 2023</start_date>
    <completion_date type="Anticipated">September 30, 2024</completion_date>
    <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>AMH</measure>
      <time_frame>1 day</time_frame>
      <description>Anti-Müllerian Hormone Test</description>
    </primary_outcome>
    <primary_outcome>
      <measure>AFC</measure>
      <time_frame>1 day</time_frame>
      <description>Antral follicle count</description>
    </primary_outcome>
    <number_of_groups>4</number_of_groups>
    <enrollment type="Anticipated">2059</enrollment>
    <condition>Infertility, Female</condition>
    <condition>Miscarriage</condition>
    <condition>Miscarriage, Recurrent</condition>
    <condition>IVF</condition>
    <arm_group>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <description>Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
      <description>Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <description>Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.ons.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>AMH ≥1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
      <description>Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.</description>
    </arm_group>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>Transvaginal ultrasound</intervention_name>
      <description>Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation</description>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <arm_group_label>AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <arm_group_label>AMH ≥1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>Blood test AMH</intervention_name>
      <description>Measurement of AMH performed on the day of first consultation</description>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
      <arm_group_label>AMH &lt;1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <arm_group_label>AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage</arm_group_label>
      <arm_group_label>AMH ≥1.3, at least 1 pregnancy and no miscarriage</arm_group_label>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          All participants who visit ART Fertility clinics in Abu Dhabi, Al Ain and Dubai for first&#xD;
          consultation&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          1. All participants with at least 1 previous pregnancy, who are assessed in one of our&#xD;
          clinics (ART Fertility Clinics Abu Dhabi, Al Ain, Dubai)&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Severe male factor (azoospermia, cryptozoospermia, severe oligoasthenoteratozoospermia&#xD;
               (OAT))&#xD;
  &#xD;
            2. Severe Endometriosis and adenomyosis based on positive anamnesis or ultrasound&#xD;
               performed in our center during the first consultation&#xD;
  &#xD;
            3. Uterine abnormalities (e.g. fibroids, different degrees of uterine septum), diagnosed&#xD;
               by ultrasound&#xD;
  &#xD;
            4. History of ovarian surgery, chemotherapy, or radiation therapy&#xD;
  &#xD;
            5. Known genetic disorder or chromosomal abnormality&#xD;
  &#xD;
            6. BMI &gt;40Kg/m2&#xD;
  &#xD;
            7. Currently using hormonal contraception or hormone replacement therapy&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <gender_based>Yes</gender_based>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
    </eligibility>
    <overall_official>
      <last_name>Laura Melado, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>ART Fertility Clinics LLC</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <phone>+971 800 337845489</phone>
      <email>barbara.lawrenz@artfertilityclinics.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Jonalyn Edades, RN</last_name>
      <phone>+971 800 337845489</phone>
      <email>jonalyn.edades@artfertilityclinics.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>ART Fertility Clinics LLC</name>
        <address>
          <city>Abu Dhabi</city>
          <zip>60202</zip>
          <country>United Arab Emirates</country>
        </address>
      </facility>
      <contact>
        <last_name>Laura Melado, PhD</last_name>
        <phone>+971 800 337845489</phone>
        <email>laura.melado@artfertilityclinics.com</email>
      </contact>
      <contact_backup>
        <last_name>Jonalyn Edades, RN</last_name>
        <phone>+971 800 337845489</phone>
        <email>jonalyn.edades@artfertilityclinics.com</email>
      </contact_backup>
      <investigator>
        <last_name>Laura Melado, PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>ART Fertility Clinics Al Ain</name>
        <address>
          <city>Al Ain</city>
          <country>United Arab Emirates</country>
        </address>
      </facility>
      <contact>
        <last_name>Anastasia Salame, MD</last_name>
        <phone>+971 800 337845489</phone>
        <email>jonalyn.edades@artfertilityclinics.com</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>ART Fertility Clinics Dubai</name>
        <address>
          <city>Dubai</city>
          <country>United Arab Emirates</country>
        </address>
      </facility>
      <contact>
        <last_name>Carol Coughlan, PhD</last_name>
        <phone>+971 800 337845489</phone>
        <email>jonalyn.edades@artfertilityclinics.com</email>
      </contact>
    </location>
    <location_countries>
      <country>United Arab Emirates</country>
    </location_countries>
    <reference>
      <citation>ESHRE working group on Ectopic Pregnancy; Kirk E, Ankum P, Jakab A, Le Clef N, Ludwin A, Small R, Tellum T, Toyli M, Van den Bosch T, Jurkovic D. Terminology for describing normally sited and ectopic pregnancies on ultrasound: ESHRE recommendations for good practice. Hum Reprod Open. 2020 Dec 16;2020(4):hoaa055. doi: 10.1093/hropen/hoaa055. eCollection 2020.</citation>
      <PMID>33354626</PMID>
    </reference>
    <reference>
      <citation>Tan J, Luo L, Jiang J, Yan N, Wang Q. Decreased Ovarian Reserves With an Increasing Number of Previous Early Miscarriages: A Retrospective Analysis. Front Endocrinol (Lausanne). 2022 Jun 10;13:859332. doi: 10.3389/fendo.2022.859332. eCollection 2022.</citation>
      <PMID>35757430</PMID>
    </reference>
    <reference>
      <citation>Bliddal S, Feldt-Rasmussen U, Forman JL, Hilsted LM, Larsen EC, Christiansen OB, Nielsen CH, Kolte AM, Nielsen HS. Anti-Mullerian hormone and live birth in unexplained recurrent pregnancy loss. Reprod Biomed Online. 2023 Jun;46(6):995-1003. doi: 10.1016/j.rbmo.2023.01.023. Epub 2023 Feb 3.</citation>
      <PMID>37055255</PMID>
    </reference>
    <reference>
      <citation>Stirrat GM. Recurrent miscarriage. II: Clinical associations, causes, and management. Lancet. 1990 Sep 22;336(8717):728-33. doi: 10.1016/0140-6736(90)92215-4.</citation>
      <PMID>1975901</PMID>
    </reference>
    <reference>
      <citation>Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003 Mar;79(3):577-84. doi: 10.1016/s0015-0282(02)04694-0.</citation>
      <PMID>12620443</PMID>
    </reference>
    <reference>
      <citation>Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, Al-Memar M, Brewin J, Abrahams VM, Maheshwari A, Christiansen OB, Stephenson MD, Goddijn M, Oladapo OT, Wijeyaratne CN, Bick D, Shehata H, Small R, Bennett PR, Regan L, Rai R, Bourne T, Kaur R, Pickering O, Brosens JJ, Devall AJ, Gallos ID, Quenby S. Recurrent miscarriage: evidence to accelerate action. Lancet. 2021 May 1;397(10285):1675-1682. doi: 10.1016/S0140-6736(21)00681-4. Epub 2021 Apr 27.</citation>
      <PMID>33915096</PMID>
    </reference>
    <reference>
      <citation>Bunnewell SJ, Honess ER, Karia AM, Keay SD, Al Wattar BH, Quenby S. Diminished ovarian reserve in recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2020 Apr;113(4):818-827.e3. doi: 10.1016/j.fertnstert.2019.11.014. Epub 2020 Mar 4.</citation>
      <PMID>32145928</PMID>
    </reference>
    <reference>
      <citation>Seifer DB. Connecting the dots between oocyte quantity and quality in diminished ovarian reserve. Fertil Steril. 2021 Apr;115(4):890. doi: 10.1016/j.fertnstert.2021.01.020. Epub 2021 Mar 6. No abstract available.</citation>
      <PMID>33750616</PMID>
    </reference>
    <reference>
      <citation>Tarasconi B, Tadros T, Ayoubi JM, Belloc S, de Ziegler D, Fanchin R. Serum antimullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril. 2017 Sep;108(3):518-524. doi: 10.1016/j.fertnstert.2017.07.001.</citation>
      <PMID>28865551</PMID>
    </reference>
    <reference>
      <citation>Lyttle Schumacher BM, Jukic AMZ, Steiner AZ. Antimullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril. 2018 Jun;109(6):1065-1071.e1. doi: 10.1016/j.fertnstert.2018.01.039. Epub 2018 Jun 2.</citation>
      <PMID>29871793</PMID>
    </reference>
    <reference>
      <citation>Atasever M, Soyman Z, Demirel E, Gencdal S, Kelekci S. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study. Fertil Steril. 2016 May;105(5):1236-1240. doi: 10.1016/j.fertnstert.2016.01.001. Epub 2016 Jan 21.</citation>
      <PMID>26806685</PMID>
    </reference>
    <reference>
      <citation>Leclercq E, de Saint Martin L, Bohec C, Le Martelot MT, Roche S, Alavi Z, Mottier D, Pasquier E. Blood anti-Mullerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage. Reprod Biomed Online. 2019 Aug;39(2):304-311. doi: 10.1016/j.rbmo.2019.04.004. Epub 2019 Apr 12.</citation>
      <PMID>31186176</PMID>
    </reference>
    <reference>
      <citation>Jaswa EG, McCulloch CE, Simbulan R, Cedars MI, Rosen MP. Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertil Steril. 2021 Apr;115(4):966-973. doi: 10.1016/j.fertnstert.2020.10.051. Epub 2021 Feb 12.</citation>
      <PMID>33583594</PMID>
    </reference>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 24, 2023</study_first_submitted>
    <study_first_submitted_qc>July 24, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 24, 2023</last_update_submitted>
    <last_update_submitted_qc>July 24, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>ART Fertility Clinics LLC</investigator_affiliation>
      <investigator_full_name>Laura Melado</investigator_full_name>
      <investigator_title>IVF Specialist</investigator_title>
    </responsible_party>
    <keyword>miscarriage</keyword>
    <keyword>infertility</keyword>
    <keyword>IVF</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Infertility</mesh_term>
      <mesh_term>Abortion, Spontaneous</mesh_term>
      <mesh_term>Infertility, Female</mesh_term>
      <mesh_term>Abortion, Habitual</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05969574
  org study id: 2305-ABU-007-LM
  nct id: NCT05969574
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  This study aims to explore the potential correlation between decreased ovarian reserve and
        previous history of early miscarriage.
  By investigating the prevalence of low ovarian reserve (LOR) in populations with specific
        reproductive histories (such as recurrent pregnancy loss, G0, and ectopic pregnancy), as well
        as the aneuploidy rates of embryos produced with Preimplantation Genetic Testing for
        Aneuploidies (PGT-A), Investigators can better understand how LOR impacts fertility outcomes
        in these populations. This information can be used to inform clinical decision-making, such
        as whether participants with LOR should consider alternative or whether they would benefit
        from additional interventions to improve ovarian function.
  
        Ultimately, by improving our understanding of how LOR impacts fertility outcomes in specific
        populations, Investigators can help to improve the overall success rates of infertility
        treatment, reduce anxiety, and distress, and help participants achieve goals of becoming
        parents.
  observational model: Cohort
  time perspective: Prospective
  measure: AMH
  time frame: 1 day
  description: Anti-Müllerian Hormone Test
  measure: AFC
  time frame: 1 day
  description: Antral follicle count
  arm group label: AMH <1.3, at least 1 pregnancy or at least 1 miscarriage
  description: Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
  arm group label: AMH <1.3, at least 1 pregnancy and no miscarriage
  description: Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
  arm group label: AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage
  description: Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.ons.
  arm group label: AMH ≥1.3, at least 1 pregnancy and no miscarriage
  description: Participants will not undergo any additional intervention compared to normal clinical assessment and routine testing of the ovarian reserve, which includes AMH and AFC. Investigators will follow standard stimulation protocols and medications.
  intervention type: Diagnostic Test
  intervention name: Transvaginal ultrasound
  description: Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
  arm group label: AMH <1.3, at least 1 pregnancy and no miscarriage
  arm group label: AMH <1.3, at least 1 pregnancy or at least 1 miscarriage
  arm group label: AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage
  arm group label: AMH ≥1.3, at least 1 pregnancy and no miscarriage
  intervention type: Diagnostic Test
  intervention name: Blood test AMH
  description: Measurement of AMH performed on the day of first consultation
  arm group label: AMH <1.3, at least 1 pregnancy and no miscarriage
  arm group label: AMH <1.3, at least 1 pregnancy or at least 1 miscarriage
  arm group label: AMH ≥ 1.3, at least 1 pregnancy or at least 1 miscarriage
  arm group label: AMH ≥1.3, at least 1 pregnancy and no miscarriage
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: Female
  gender based: Yes
  minimum age: N/A
  maximum age: N/A
  last name: Laura Melado, PhD
  role: Principal Investigator
  affiliation: ART Fertility Clinics LLC
  last name: Barbara Lawrenz, PhD
  phone: +971 800 337845489
  email: barbara.lawrenz@artfertilityclinics.com
  last name: Jonalyn Edades, RN
  phone: +971 800 337845489
  email: jonalyn.edades@artfertilityclinics.com
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  facility: 
  contact: 
  country: United Arab Emirates
  citation: ESHRE working group on Ectopic Pregnancy; Kirk E, Ankum P, Jakab A, Le Clef N, Ludwin A, Small R, Tellum T, Toyli M, Van den Bosch T, Jurkovic D. Terminology for describing normally sited and ectopic pregnancies on ultrasound: ESHRE recommendations for good practice. Hum Reprod Open. 2020 Dec 16;2020(4):hoaa055. doi: 10.1093/hropen/hoaa055. eCollection 2020.
  PMID: 33354626
  citation: Tan J, Luo L, Jiang J, Yan N, Wang Q. Decreased Ovarian Reserves With an Increasing Number of Previous Early Miscarriages: A Retrospective Analysis. Front Endocrinol (Lausanne). 2022 Jun 10;13:859332. doi: 10.3389/fendo.2022.859332. eCollection 2022.
  PMID: 35757430
  citation: Bliddal S, Feldt-Rasmussen U, Forman JL, Hilsted LM, Larsen EC, Christiansen OB, Nielsen CH, Kolte AM, Nielsen HS. Anti-Mullerian hormone and live birth in unexplained recurrent pregnancy loss. Reprod Biomed Online. 2023 Jun;46(6):995-1003. doi: 10.1016/j.rbmo.2023.01.023. Epub 2023 Feb 3.
  PMID: 37055255
  citation: Stirrat GM. Recurrent miscarriage. II: Clinical associations, causes, and management. Lancet. 1990 Sep 22;336(8717):728-33. doi: 10.1016/0140-6736(90)92215-4.
  PMID: 1975901
  citation: Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003 Mar;79(3):577-84. doi: 10.1016/s0015-0282(02)04694-0.
  PMID: 12620443
  citation: Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, Al-Memar M, Brewin J, Abrahams VM, Maheshwari A, Christiansen OB, Stephenson MD, Goddijn M, Oladapo OT, Wijeyaratne CN, Bick D, Shehata H, Small R, Bennett PR, Regan L, Rai R, Bourne T, Kaur R, Pickering O, Brosens JJ, Devall AJ, Gallos ID, Quenby S. Recurrent miscarriage: evidence to accelerate action. Lancet. 2021 May 1;397(10285):1675-1682. doi: 10.1016/S0140-6736(21)00681-4. Epub 2021 Apr 27.
  PMID: 33915096
  citation: Bunnewell SJ, Honess ER, Karia AM, Keay SD, Al Wattar BH, Quenby S. Diminished ovarian reserve in recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2020 Apr;113(4):818-827.e3. doi: 10.1016/j.fertnstert.2019.11.014. Epub 2020 Mar 4.
  PMID: 32145928
  citation: Seifer DB. Connecting the dots between oocyte quantity and quality in diminished ovarian reserve. Fertil Steril. 2021 Apr;115(4):890. doi: 10.1016/j.fertnstert.2021.01.020. Epub 2021 Mar 6. No abstract available.
  PMID: 33750616
  citation: Tarasconi B, Tadros T, Ayoubi JM, Belloc S, de Ziegler D, Fanchin R. Serum antimullerian hormone levels are independently related to miscarriage rates after in vitro fertilization-embryo transfer. Fertil Steril. 2017 Sep;108(3):518-524. doi: 10.1016/j.fertnstert.2017.07.001.
  PMID: 28865551
  citation: Lyttle Schumacher BM, Jukic AMZ, Steiner AZ. Antimullerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. Fertil Steril. 2018 Jun;109(6):1065-1071.e1. doi: 10.1016/j.fertnstert.2018.01.039. Epub 2018 Jun 2.
  PMID: 29871793
  citation: Atasever M, Soyman Z, Demirel E, Gencdal S, Kelekci S. Diminished ovarian reserve: is it a neglected cause in the assessment of recurrent miscarriage? A cohort study. Fertil Steril. 2016 May;105(5):1236-1240. doi: 10.1016/j.fertnstert.2016.01.001. Epub 2016 Jan 21.
  PMID: 26806685
  citation: Leclercq E, de Saint Martin L, Bohec C, Le Martelot MT, Roche S, Alavi Z, Mottier D, Pasquier E. Blood anti-Mullerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage. Reprod Biomed Online. 2019 Aug;39(2):304-311. doi: 10.1016/j.rbmo.2019.04.004. Epub 2019 Apr 12.
  PMID: 31186176
  citation: Jaswa EG, McCulloch CE, Simbulan R, Cedars MI, Rosen MP. Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertil Steril. 2021 Apr;115(4):966-973. doi: 10.1016/j.fertnstert.2020.10.051. Epub 2021 Feb 12.
  PMID: 33583594
  responsible party type: Principal Investigator
  investigator affiliation: ART Fertility Clinics LLC
  investigator full name: Laura Melado
  investigator title: IVF Specialist
  mesh term: Infertility
  mesh term: Abortion, Spontaneous
  mesh term: Infertility, Female
  mesh term: Abortion, Habitual